Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer

Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of brain metastases in <em>EGFR</em>-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.

Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of treating brain metastases inEGFR-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.

In the FLAURA trial, presented at the 2019 European Lung Cancer Congress, osimertinib showed intracranial responses.